Prognostic Model of Rituximab in the Treatment of MN

Conditions

• Idiopathic Membranous Nephropathy

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• Rituximab — DRUG
  375mg/m2 once a week, 4 times in total, or 1g intravenous drip, once again after 2 weeks, twice in total.

Study Details

The goal of this observational study is to explore the factors that can predict the prognosis difference in patients with idiopathic membranous nephropathy (IMN) under the treatment of rituximab. The main questions it aims to answer are: * to explore the factors that can predict the prognosis difference in patients with IMN under the treatment of rituximab * to establish a clinical prediction model and verify it to provide a reference for the early Participants will receive standard the treatment of rituximab treatment and will then be divided into remission and non remission groups based on the treatment effect after the standard treatment cycle. Blood, urine, and fecal samples were collected from patients to explore possible factors influencing treatment efficacy. Researchers will compare \[remission group and non-remission group\] to see if the gut microbiota and its metabolites are factors that influence the efficacy of treatment.

Key Dates

Start date

Jun 30, 2023

Status verified

Mar 2023

Primary completion

Jul 31, 2023

Completion

Dec 31, 2023

Study Design

Enrollment

50 participants (estimated)

Arms

• Arm: Remission
• Arm: Non-remission

Primary Outcome Measure

Remission of the State of MN [ Time Frame: 6 months ]